MarginsXMarginsX
Home › Markets › Health Care › NXTC

NextCure Inc. (NXTC)

NXTC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.68
+4.38% on the day
Market cap
$30.6M
Nano cap
Revenue · 2020
$22.4M
+252.6% on 2019
Net income · 2020
-$36.6M
-163.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1661059/000155837022002824/0001558370-22-002824-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.

Profile

FieldValue
TickerNXTC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2019
SEC CIK0001661059
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2020

LineValue
Revenue$22.4M
Net income-$36.6M
Operating income-$41.2M
Net margin-163.6%
Operating margin-184.2%
Revenue growth+252.6%
Cash$32.8M
Total assets$306.6M
P/E (computed)Net income was not positive
P/S (computed)1.4×

Warning signs

Cash runway
2.4 months
$8.7M cash at September 30, 2026
Share count, 1 year
+70.9%
2025-10-31 to 2026-11-09 · +96.9% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$1.4M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern."
10-Q 2026-11-10
Cash and burn$8.7M cash; operating cash flow -$10.7M a quarter.Report 2026-09-30
Shares outstanding4,579,023 (2026-11-09); 2,679,822 a year earlier; 27,903,027 three years earlier. 3y figure adjusted for split (1-for-12 overall).Cover page 2026-11-09
Reverse splits, 3 years1; latest 1-for-12 on 2025-07-14Source 2025-07-14
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2025-12-19
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Baltimore, Maryland, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.6M, sold $185K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$6.8M-$12.1M$8.7MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$14.9M-$9.7M$15.3MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$9.8M-$13.4M$15.2MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$9.4M-$7.6M$26.0MNo debt tagsNeeds four quarters10-K 2026-03-05
Q3 2025
2025-09-30
Not filed-$8.6M-$6.3M$7.3MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$26.8M-$22.7M$4.9MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$11.0M-$13.0M$21.8MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$11.6M-$7.0M$27.7MNo debt tagsNeeds four quarters10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-11-06
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 402 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+20.1%
1 month+1.9%
3 months-22.7%
Year to date-54.9%
1 year-34.4%
From 52-week high-55.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NSRXNasus Pharma Ltd.$2.66-7.32%$31.2M
PMNProMIS Neurosciences Inc. Common Shares (ON)$3.31+0.61%$29.8M
NNVCNanoViricides Inc.$1.24+0.81%$31.7M
SCYXSCYNEXIS Inc.$2.91-9.35%$29.0M
BCTXBriaCell Therapeutics Corp. Common Shares$3.30-2.65%$28.8M
AARDAardvark Therapeutics Inc.$1.26-5.26%$27.6M
RNTXRein Therapeutics Inc.$0.4000-27.55%$34.5M
RMTIRockwell Medical Inc.$6.76-4.38%$26.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier